Obsidian Therapeutics (OBX) awards 37,653 stock options to director Fardis
Rhea-AI Filing Summary
Obsidian Therapeutics, Inc. director Maria Fardis received a compensatory stock option grant for 37,653 shares of common stock on August 3, 2026. The option has an exercise price of $12.00 per share and expires on August 2, 2036. The shares underlying this option vest and become exercisable upon the earlier of the one-year anniversary of the grant date or the issuer's annual meeting of stockholders following the grant date, subject to her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Fardis Maria
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 37,653 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 37,653 shares (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Key Figures
Options granted: 37,653 shares
Exercise price: $12.00 per share
Expiration date: August 2, 2036
+1 more
4 metrics
Options granted
37,653 shares
Stock option grant to director on August 3, 2026
Exercise price
$12.00 per share
Exercise price of stock options granted to director
Expiration date
August 2, 2036
Expiration of stock options granted to director
Underlying shares
37,653 shares
Common shares underlying the granted stock options
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price is given as the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders regulatory
"the Issuer's annual meeting of stockholders following the grant date"
FAQ
What did Obsidian Therapeutics (OBX) director Maria Fardis receive in this Form 4?
Maria Fardis received a stock option grant for 37,653 shares of Obsidian Therapeutics common stock, with terms tied to future vesting and an expiration in 2036.
What is the exercise price of the options reported for OBX in this Form 4?
The options granted to Maria Fardis carry an exercise price of $12.00 per share. This is the price at which she may purchase Obsidian Therapeutics common shares once the options vest.
When do Maria Fardis’s OBX options vest according to the Form 4?
The options vest upon the earlier of one year after the grant date or the date of Obsidian Therapeutics’ annual stockholders’ meeting following the grant, subject to her continued service with the company.
What is the expiration date of the OBX stock options granted to Maria Fardis?
The stock options granted to Maria Fardis expire on August 2, 2036. After this date, any unexercised options will no longer be exercisable for Obsidian Therapeutics common stock.
How many OBX options does Maria Fardis hold after this reported transaction?
Following this grant, Maria Fardis holds 37,653 stock options as reported, each representing the right to acquire one share of Obsidian Therapeutics common stock at the stated exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
